OUH - Clinical trials

Nyen JE, Booth AØ, Husby Ø, Bugge C, Engebretsen I, Oteiza F, Helland Å, Fjellbirkeland L, Brustugun OT, Grønberg BH (2025)
Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients - a nationwide and longitudinal study
Front Oncol, 15, 1506041
DOI 10.3389/fonc.2025.1506041, PubMed 40052133

Brant SB, Børø S, Jonasson C, Helland Å, Thoresen S (2025)
Comparative Effectiveness of First-Line Pembrolizumab vs. Chemotherapy in aNSCLC: A Norwegian Population-Based Cohort Study
Clin Pharmacol Ther, 117 (4), 1123-1130
DOI 10.1002/cpt.3591, PubMed 39916352

Rakaee M, Tafavvoghi M, Ricciuti B, Alessi JV, Cortellini A, Citarella F, Nibid L, Perrone G, Adib E, Fulgenzi CAM, Hidalgo Filho CM, Di Federico A, Jabar F, Hashemi S, Houda I, Richardsen E, Rasmussen Busund LT, Donnem T, Bahce I, Pinato DJ, Helland Å, Sholl LM, Awad MM, Kwiatkowski DJ (2025)
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer
JAMA Oncol, 11 (2), 109-118
DOI 10.1001/jamaoncol.2024.5356, PubMed 39724105

More publications


Durvalumab (MEDI4736) After chemoRadioTherapy for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients More information	Nivolumab and Ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma – a phase II randomised clinical and translational trial More information
	NorPACT-2
Immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer (COM-IT-2) – a phase II randomised clinical and translational trial More information	Norwegian Pancreatic Cancer Trial (NorPACT)-2: Liquid biopsies and blood-based biomarkers (https://www.ous-research.no/ pancreaticcancer)

NorPACT-2